MRNA Beats on Q2 Earnings & Sales, Stock Down on Lowered Sales View

Moderna MRNA incurred a loss of $2.13 per share in the second quarter of 2025, narrower than the Zacks Consensus Estimate of a loss of $2.99. In the year-ago period, the company had reported a loss of $3.33.Total revenues in the quarter were $142 million, which beat the Zacks Consensus...